AbbVie Spotlights Its Early-Stage R&D Pipeline
Executive Summary
A group of early-stage investigational cancer, myelofibrosis and immune-oncology products have been tagged by AbbVie as potential therapies of interest longer term.
You may also be interested in...
Countdown To The Allergan Merger, And More From AbbVie’s Q4 Earnings
Despite Humira’s ex-US sales erosion, AbbVie reports strong launches for Skyrizi and Rinvoq, continued growth for hematological oncology franchise, and boasts it has a thriving R&D engine.
AbbVie Puts Final Nail In Rova-T's Coffin After Another Trial Failure
AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.
Patience Pays Off For Kyowa Kirin As Nourianz Finally Gets US FDA OK
The Japanese firm's original 2007 NDA was rejected in 2008 but it kept faith in the drug, now approved as an adjunct to levodopa/carbidopa. At least one competitor is waiting in the wings.